These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3311616)

  • 1. Consensus development summaries. The management of clinically localized prostate cancer. National Institutes of Health.
    Conn Med; 1987 Sep; 51(9):607-10. PubMed ID: 3311616
    [No Abstract]   [Full Text] [Related]  

  • 2. Consensus statement: the Management of Clinically Localized Prostate Cancer. National Institutes of Health Consensus Development Panel.
    NCI Monogr; 1988; (7):3-6. PubMed ID: 3050539
    [No Abstract]   [Full Text] [Related]  

  • 3. The management of clinically localized prostate cancer. A summary of the Consensus Statement of the National Institutes of Health.
    Halperin EC; Fraser RW; Hughes J
    N C Med J; 1988 Feb; 49(2):75-9. PubMed ID: 3278241
    [No Abstract]   [Full Text] [Related]  

  • 4. The management of clinically localized prostate cancer.
    Natl Inst Health Consens Dev Conf Consens Statement; 1987 Jun 15-17; 6(10):1-6. PubMed ID: 3317009
    [No Abstract]   [Full Text] [Related]  

  • 5. NIH Consensus Development Conference. Management of clinically localized prostate cancer.
    Oncology (Williston Park); 1987 Nov; 1(9):46-9, 54. PubMed ID: 3079494
    [No Abstract]   [Full Text] [Related]  

  • 6. National Institutes of Health Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. Bethesda, Maryland, June 15-17, 1987.
    NCI Monogr; 1988; (7):1-174. PubMed ID: 3050532
    [No Abstract]   [Full Text] [Related]  

  • 7. Consensus conference. The management of clinically localized prostate cancer.
    JAMA; 1987 Nov; 258(19):2727-30. PubMed ID: 3312666
    [No Abstract]   [Full Text] [Related]  

  • 8. The management of clinically localized prostate cancer. National Institutes of Health Consensus Development Conference, June 15-17, 1987.
    J Urol; 1987 Dec; 138(6):1369-75. PubMed ID: 3316713
    [No Abstract]   [Full Text] [Related]  

  • 9. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer.
    Hennenfent BR
    Br J Urol; 1998 Jul; 82(1):166. PubMed ID: 9698691
    [No Abstract]   [Full Text] [Related]  

  • 10. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer.
    Dahm P; Yeung LL; Chang SS; Cookson MS
    J Urol; 2008 Aug; 180(2):451-9; discussion 460. PubMed ID: 18550100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: Improving outcomes for primary and salvage therapy of localized prostate cancer.
    Schellhammer PF
    J Urol; 2003 Nov; 170(5):1841-2. PubMed ID: 14532788
    [No Abstract]   [Full Text] [Related]  

  • 12. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes.
    Barry MJ; Fleming C; Coley CM; Wasson JH; Fahs MC; Oesterling JE
    Urology; 1995 Sep; 46(3):277-89. PubMed ID: 7544931
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diagnosis and treatment of prostate cancer].
    Auvert J
    Ann Urol (Paris); 1999; 33(4):259-62. PubMed ID: 10510707
    [No Abstract]   [Full Text] [Related]  

  • 14. Conservative management of clinically-localized prostate cancer.
    Chodak G
    Can J Oncol; 1994 Nov; 4 Suppl 1():20-1; discussion 22-3. PubMed ID: 8853484
    [No Abstract]   [Full Text] [Related]  

  • 15. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
    Gore JL; Kwan L; Lee SP; Reiter RE; Litwin MS
    J Natl Cancer Inst; 2009 Jun; 101(12):888-92. PubMed ID: 19509365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy.
    D'Amico AV; Desjardin A; Chung A; Chen MH; Schultz D; Whittington R; Malkowicz SB; Wein A; Tomaszewski JE; Renshaw AA; Loughlin K; Richie JP
    Cancer; 1998 May; 82(10):1887-96. PubMed ID: 9587121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
    Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
    J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy.
    Choo R; Kawakami J; Siemens R; Davis BJ; Brundage M; Pisansky TM
    BJU Int; 2006 Oct; 98(4):773-6. PubMed ID: 16978271
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of stage A1 prostate cancer: the case for treatment.
    Bahnson RR
    Semin Urol; 1993 May; 11(2):54-7. PubMed ID: 7689739
    [No Abstract]   [Full Text] [Related]  

  • 20. Urologic cancer research at the National Cancer Institute.
    Chiarodo A
    Semin Urol; 1993 Feb; 11(1):2-6. PubMed ID: 8465123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.